BSE filing, NSE: SOBME. Summary written from the filing by ALFA Finder's alert engine.
Sobhagya Mercantile Ltd: key numbers
- Share price
- ₹1,275.00
- Market cap
- ₹1,071 Cr
- Revenue (annual)
- ₹232.5 Cr
- Net profit (annual)
- ₹22.04 Cr
- P/E (TTM)
- 52.3×Sector 46.5×
- Promoter holding
- 60.58%-4.04% QoQ
- FII holding
- 19.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sobhagya Mercantile Ltd
All →Sobhagya Mercantile Board Meeting Date
Sobhagya Mercantile intimated a board meeting on 13 November 2026 to approve Q2/H1 results, a share capital increase and a bonus issue. Trading window closure and an EGM notice are also on the agenda.
Sobhagya Mercantile Other Announcement
Sobhagya Mercantile Ltd filed a NIL confirmation certificate under Regulation 74(5) for the quarter ended September 30, 2026, as mandated by SEBI regulations.
Sobhagya Mercantile Annual General Meeting
Sobhagya Mercantile Limited held its 42nd Annual General Meeting on 29th September 2026. The meeting transacted ordinary and special business as per the agenda.
Sobhagya Mercantile Annual General Meeting
Sobhagya Mercantile Limited has issued the notice for its 42nd Annual General Meeting, scheduled to be held on September 29, 2026, via video conferencing.
Sobhagya Mercantile Annual Report
Sobhagya Mercantile Limited submitted its Annual Report for FY 2025-26. The 42nd Annual General Meeting is scheduled for September 29, 2026.
Sobhagya Mercantile Other Announcement
Sobhagya Mercantile Limited has appointed L M A & Associates as the Cost Auditor of the company for a term of 12 months.
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.